Global CD30 (TNFRSF8) Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global CD30 (TNFRSF8) Antibody Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
CD30 (TNFRSF8) Antibody is an antibody specific for CD30 protein.
CD30 (TNFRSF8) Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD30 (TNFRSF8) Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Demand from Flow Cytometry and ELISA are the major drivers for the industry.
CD30 is a member of the tumor necrosis factor receptor superfamily, mainly expressed on the surface of lymphocytes and some cancer cells. It plays a role in the regulation of cell growth, survival and differentiation, and its expression is increased in some malignant tumors such as lymphoma. The application of CD30 antibody can help to study the expression pattern and function of CD30 protein, especially in tumor research to help analyze its mechanism of action. In view of the important role of CD30 in cancer, CD30 antibody has potential application value in tumor therapy, diagnosis and research, and may provide useful information and tools for related fields.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD30 (TNFRSF8) Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD30 (TNFRSF8) Antibody market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of CD30 (TNFRSF8) Antibody, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the CD30 (TNFRSF8) Antibody industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of CD30 (TNFRSF8) Antibody in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, CD30 (TNFRSF8) Antibody introduction, etc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of CD30 (TNFRSF8) Antibody market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
CD30 (TNFRSF8) Antibody report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global CD30 (TNFRSF8) Antibody market is projected to reach US$ 894.4 million in 2029, increasing from US$ 394.6 million in 2022, with the CAGR of 12.4% during the period of 2024 to 2029. Demand from Flow Cytometry and ELISA are the major drivers for the industry.
CD30 is a member of the tumor necrosis factor receptor superfamily, mainly expressed on the surface of lymphocytes and some cancer cells. It plays a role in the regulation of cell growth, survival and differentiation, and its expression is increased in some malignant tumors such as lymphoma. The application of CD30 antibody can help to study the expression pattern and function of CD30 protein, especially in tumor research to help analyze its mechanism of action. In view of the important role of CD30 in cancer, CD30 antibody has potential application value in tumor therapy, diagnosis and research, and may provide useful information and tools for related fields.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global CD30 (TNFRSF8) Antibody market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Sino Biological, Inc.
Bio-Techne
Thermo Fisher Scientific (China) Co., Ltd.
Boster Biological Technology
MyBiosource, Inc.
Abeomics Inc.
Abbexa
Cell Signaling Technology, Inc.
Creative Diagnostics
OriGene Technologies, Inc.
Merck
Cayman Chemical
CUSABIO
Biotium
BioLegend
Abcepta
ProSci Incorporated
Segment by Type
Monoclonal Antibody
Polyclonal Antibody
Segment by Application
Flow Cytometry
ELISA
Western Blot
Immunofluorescence
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the CD30 (TNFRSF8) Antibody market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of CD30 (TNFRSF8) Antibody, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the CD30 (TNFRSF8) Antibody industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of CD30 (TNFRSF8) Antibody in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, CD30 (TNFRSF8) Antibody introduction, etc. CD30 (TNFRSF8) Antibody Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of CD30 (TNFRSF8) Antibody market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices